Flash Player 9 or higher is required to view the chart Click here to download Flash Player now

Echo plans to enroll in the clinical study up to twenty-five (25) patients with either Type 1 or Type 2 diabetes and to compare data obtained from its Symphony tCGM System with both the YSI 2300 STAT Plus Glucose Analyzer and a commercially available professional-use glucometer.  The study is expected to collect more than 2400 data pairs to be used in the analyses by taking frequent reference glucose measurements for 24 hours.  The study data will be blinded to study subjects and study personnel. A comparison of the data relative to the reference blood glucose values will be used to assess the accuracy of Symphony.

Last Thursday, ECTE announced positive results from its clinical study of its Symphony tCGM System; its lead program in analyte monitoring- a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system. Shares jumped from $2.74 to $3.30 on the news and have developed some new support at the $3 mark.

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

---

Add this page to your favorite Social Bookmarking websites